Jump to content

WuXi AppTec: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
AM WuXi (talk | contribs)
15 edits
Updated names of WuXi AppTec entities as direct edits as per Talk page discussion
Line 12: Line 12:
| location = [[Shanghai]], [[China]]
| location = [[Shanghai]], [[China]]
| locations = 18, including in China and USA
| locations = 18, including in China and USA
| num_employees = >14,000 (2017)<ref name="About WuXi AppTec">{{cite web |title=Company Profile |url=http://www.wuxiapptec.com/about_us.html |publisher=WuXi AppTec |access-date=12 July 2017 |url-status=dead |archive-url=https://web.archive.org/web/20170705061701/http://www.wuxiapptec.com/about_us.html |archive-date=5 July 2017}}</ref>
| num_employees = >14,000 (2017)<ref name="About WuXi AppTec">{{cite web |title=Company Profile |url= http://www.wuxiapptec.com/about_us.html |publisher=WuXi AppTec |access-date=12 July 2017 |url-status=dead |archive-url=https://web.archive.org/web/20170705061701/http://www.wuxiapptec.com/about_us.html |archive-date=5 July 2017}}</ref>
| website = {{URL|https://www.wuxiapptec.com/}}
| website = {{URL| https://www.wuxiapptec.com/}}
| industry = [[Contract Research Organization]]s<br />[[Pharmaceutical]]<br/>[[Biopharmaceutical]] <br/> [[Medical Devices]]
| industry = [[Contract Research Organization]]s<br />[[Pharmaceutical]]<br/>[[Biopharmaceutical]] <br/> [[Medical Devices]]
| products =
| products =
| traded_as = {{SSE|603259}}
| traded_as = {{SSE|603259}}
}}
}}
Line 23: Line 23:


==History==
==History==
WuXi's founder is Dr. [[Ge Li]],<ref name="WuXi AppTec leadership">{{cite web |title=Company Profile/ leadership |url=https://www.wuxiapptec.com/about/leadership |publisher=WuXi AppTec |access-date=29 March 2021}}</ref> an organic chemist, who founded WuXi PharmaTech in [[Shanghai]] in December 2000.<ref name="WuXi AppTec History">{{cite web |title=Company Profile/ History |url=https://www.wuxiapptec.com/about/history |publisher=WuXi AppTec |access-date=29 March 2021}}</ref>
WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Dr. [[Ge Li]].<ref name="WuXi AppTec leadership">{{cite web |title=Company Profile/ leadership |url= https://www.wuxiapptec.com/about/leadership |publisher=WuXi AppTec |access-date=29 March 2021}}</ref>
<ref name="WuXi AppTec History">{{cite web |title=Company Profile/ History |url= https://www.wuxiapptec.com/about/history |publisher=WuXi AppTec |access-date=29 March 2021}}</ref>
WuXi established services in [[Chemical synthesis|synthetic chemistry]] in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006.<ref>{{cite press release|url=https://en.prnasia.com/releases/global/WuXi_PharmaTech_Listed_among_Asia_s_Fastest_Growing_Companies_Third_Year_Running-646.shtml|title=WuXi PharmaTechListed Among Asia's Fastest Growing Companies, Third Year Running|date=14 December 2006|publisher=WuXi PharmaTech|via=PRNewswire|access-date=24 June 2020}}</ref> The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. In the same year the company was renamed ''WuXi AppTec''.<ref>{{cite web |url=https://www.wuxiapptec.com/about/history |title=Our History |publisher=WuXi AppTec |access-date=26 December 2023}}</ref> WuXi opened a toxicology facility in [[Suzhou]] in 2009.<ref name="WuXi AppTec - Company History">{{cite web|date=29 March 2019<!--based on page security certificate-->|title=Our History|url=https://www.wuxiapptec.com/about/history|access-date=24 June 2020|publisher=WuXi AppTec}}</ref>
WuXi PharmaTech established services in [[Chemical synthesis|synthetic chemistry]] in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006.<ref>{{cite press release|url=https://en.prnasia.com/releases/global/WuXi_PharmaTech_Listed_among_Asia_s_Fastest_Growing_Companies_Third_Year_Running-646.shtml|title=WuXi PharmaTechListed Among Asia's Fastest Growing Companies, Third Year Running|date=14 December 2006|publisher=WuXi PharmaTech|via=PRNewswire|access-date=24 June 2020}}</ref> The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. Following this acquisition, the company was renamed WuXi AppTec.<ref>{{Cite web|last1=Nagaraj|first1=Amulya|last2=Shen|first2=Samuel|title=WuXi to acquire U.S.-based biopharmaceutical company|url=https://www.reuters.com/article/us-china-wuxi-acquisition-idUKPEK23688220080104/|date=4 January 2008|website=reuters.com}}</ref> In the same year the company was renamed ''WuXi AppTec''.<ref>{{cite web |url= https://www.wuxiapptec.com/about/history |title=Our History |publisher=WuXi AppTec |access-date=26 December 2023}}</ref> WuXi AppTec opened a toxicology facility in [[Suzhou]] in 2009.<ref name="WuXi AppTec - Company History">{{cite web|date=29 March 2019<!--based on page security certificate-->|title=Our History|url=https://www.wuxiapptec.com/about/history|access-date=24 June 2020|publisher=WuXi AppTec}}</ref>


WuXi opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in [[Shanghai]] and [[Wuxi City]] in 2011. At the same year, WuXi acquired MedKey, a China-based clinical research company,<ref>[https://www.genengnews.com/topics/drug-discovery/wuxi-acquires-chinese-clinical-cros-medkey-and-jiecheng/ WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng] 24 October 2011 ''www.genengnews.com'', accessed 28 March 2021</ref> and [[Abgent]], a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery.<ref>[https://www.fiercebiotech.com/biotech/wuxi-pharmatech-acquires-abgent-a-leading-producer-of-biological-research-reagents WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents] 14 October 2011 ''www.fiercebiotech.com'', accessed 28 March 2021</ref> In 2012, WuXi opened a chemistry facility in [[Wuhan]] and a GMP biologics drug-substance facility in Wuxi City. That year WuXi also entered into a joint venture with [[MedImmune]], the biologics arm of [[AstraZeneca]], to co-develop MEDI5117, an anti-IL6 antibody for [[rheumatoid arthritis]] for the Chinese market.<ref>[https://www.biospectrumasia.com/news/28/1330/medimmune-wuxi-form-joint-venture.html MedImmune, WuXi form joint venture] 10 September 2012 ''www.biospectrumasia.com'', accessed 28 March 2021</ref> In 2013, WuXi formed a joint venture with the global clinical [[contract research organization]] PRA International (now called [[PRA Health Sciences]]) to build a clinical research business in China.<ref>[http://www.pmlive.com/pharma_news/wuxi_and_pra_form_chinese_joint_venture_458040 WuXi and PRA form Chinese joint venture] 8 January 2013 ''www.pmlive.com'', accessed 28 March 2021</ref>
WuXi AppTec's subsidiary, WuXi STA, opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in [[Shanghai]] and [[Wuxi City]] in 2011. At the same year, WuXi AppTec acquired MedKey, a China-based clinical research company,<ref>[ https://www.genengnews.com/topics/drug-discovery/wuxi-acquires-chinese-clinical-cros-medkey-and-jiecheng/ WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng] 24 October 2011 ''www.genengnews.com'', accessed 28 March 2021</ref> and [[Abgent]], a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery.<ref>[ https://www.fiercebiotech.com/biotech/wuxi-pharmatech-acquires-abgent-a-leading-producer-of-biological-research-reagents WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents] 14 October 2011 ''www.fiercebiotech.com'', accessed 28 March 2021</ref> In 2012, WuXi AppTec opened a chemistry facility in [[Wuhan]] and a GMP biologics drug-substance facility in Wuxi City. That year WuXi AppTec also entered into a joint venture with [[MedImmune]], the biologics arm of [[AstraZeneca]], to co-develop MEDI5117, an anti-IL6 antibody for [[rheumatoid arthritis]] for the Chinese market.<ref>[ https://www.biospectrumasia.com/news/28/1330/medimmune-wuxi-form-joint-venture.html MedImmune, WuXi form joint venture] 10 September 2012 ''www.biospectrumasia.com'', accessed 28 March 2021</ref> In 2013, WuXi AppTec formed a joint venture with the global clinical [[contract research organization]] PRA International (now called [[PRA Health Sciences]]) to build a clinical research business in China.<ref>[ http://www.pmlive.com/pharma_news/wuxi_and_pra_form_chinese_joint_venture_458040 WuXi and PRA form Chinese joint venture] 8 January 2013 ''www.pmlive.com'', accessed 28 March 2021</ref>


In 2014, WuXi opened a new biologics biosafety testing facility in [[Suzhou]]. In the same year, WuXi acquired [[Xenobiotic|XenoBiotic]] Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.<ref>[https://www.thepharmaletter.com/article/wuxi-pharmatech-acquires-xenobiotic-labs WuXi PharmaTech acquires XenoBiotic Labs] 1 October 2014 ''www.thepharmaletter.com'', accessed 28 March 2021</ref>
In 2014, WuXi AppTec opened a new biologics biosafety testing facility in [[Suzhou]]. In the same year, WuXi AppTec acquired [[Xenobiotic|XenoBiotic]] Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.<ref>[ https://www.thepharmaletter.com/article/wuxi-pharmatech-acquires-xenobiotic-labs WuXi PharmaTech acquires XenoBiotic Labs] 1 October 2014 ''www.thepharmaletter.com'', accessed 28 March 2021</ref>


In 2015, WuXi completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion.<ref>[https://www.conyers.com/publications/view/conyers-advises-new-wuxi-life-science-ltd-in-connection-with-us-3-3-billion-buyout/ Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout] ''www.conyers.com'', accessed 29 March 2021</ref> In 2016, WuXi's STA subsidiary opened a new campus in [[Changzhou]]<ref>[https://www.biospace.com/article/releases/wuxi-apptec-s-sta-subsidiary-opens-new-campus-in-changzhou-/ WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou] 4 March 2016 ''www.biospace.com'', accessed 29 March 2021</ref> and operations in San Diego. In the same year, WuXi acquired Crelux GmbH, a structure-based drug discovery provider based in [[Munich|Munich, Germany]].<ref>[https://biopharma-asia.com/sections/wuxi-apptec-acquire-crelux-gmbh/ WuXi Apptec acquire Crelux GmbH] 19 April 2016 ''biopharma-asia.com'', accessed 29 March 2021</ref> In 2017, WuXi acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).<ref>[https://www.centerwatch.com/articles/14195 WuXi AppTec acquires HD Biosciences] 20 January 2017 ''www.centerwatch.com'', accessed 29 March 2021</ref>
In 2015, WuXi AppTec completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion.<ref>[ https://www.conyers.com/publications/view/conyers-advises-new-wuxi-life-science-ltd-in-connection-with-us-3-3-billion-buyout/ Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout] ''www.conyers.com'', accessed 29 March 2021</ref> In 2016, WuXi STA opened a new campus in [[Changzhou]]<ref>[ https://www.biospace.com/article/releases/wuxi-apptec-s-sta-subsidiary-opens-new-campus-in-changzhou-/ WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou] 4 March 2016 ''www.biospace.com'', accessed 29 March 2021</ref> and operations in San Diego. In the same year, WuXi AppTec acquired Crelux GmbH, a structure-based drug discovery provider based in [[Munich|Munich, Germany]].<ref>[ https://biopharma-asia.com/sections/wuxi-apptec-acquire-crelux-gmbh/ WuXi Apptec acquire Crelux GmbH] 19 April 2016 ''biopharma-asia.com'', accessed 29 March 2021</ref> In 2017, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).<ref>[ https://www.centerwatch.com/articles/14195 WuXi AppTec acquires HD Biosciences] 20 January 2017 ''www.centerwatch.com'', accessed 29 March 2021</ref>


==Company segments and subsidiaries==
==Company segments and subsidiaries==
Line 43: Line 44:


===WuXi NextCODE===
===WuXi NextCODE===
In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of [[DeCODE genetics#NextCODE Health|NextCODE Health]], a [[bioinformatics]] [[startup company]] which emerged from the Icelandic firm deCODE genetics in 2013.<ref>{{Cite news|last=Fidler|first=Ben|date=23 October 2013|title=DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris|work=Xconomy|location=Boston|url=https://xconomy.com/boston/2013/10/23/decode-spinout-nextcode-health-launches-15m-arch-polaris/|access-date=24 June 2020}}</ref><ref name=":0">{{Cite web|date=22 April 2020<!--based on security certificate-->|title=WuXi NextCode|url=https://www.fastcompany.com/company/wuxi-nextcode|access-date=24 June 2020|publisher=Fast Company}}</ref> The subsidiary had offices in Boston and Woburn, Massachusetts (US); Reykjavik (Iceland) and Shanghai (China).<ref name=":0" />
In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of [[DeCODE genetics#NextCODE Health|NextCODE Health]], a [[bioinformatics]] [[startup company]] which emerged from the Icelandic firm deCODE genetics in 2013.<ref>{{Cite news|last=Fidler|first=Ben|date=23 October 2013|title=DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris|work=Xconomy|location=Boston|url=https://xconomy.com/boston/2013/10/23/decode-spinout-nextcode-health-launches-15m-arch-polaris/|access-date=24 June 2020}}</ref><ref name=":0">{{Cite web|date=22 April 2020<!--based on security certificate-->|title=WuXi NextCode|url=https://www.fastcompany.com/company/wuxi-nextcode|access-date=24 June 2020|publisher=Fast Company}}</ref> The subsidiary had offices in Boston and Woburn, Massachusetts (US); Reykjavik (Iceland) and Shanghai (China).<ref name=":0" />


==References==
==References==
Line 55: Line 56:
{{SSE 50 companies}}
{{SSE 50 companies}}
{{FTSE China A50 Index}}
{{FTSE China A50 Index}}
{{Hang Seng China 50 Index}}
{{Hang Seng China 50 Index}}

{{Authority control}}
{{Authority control}}


Revision as of 18:41, 3 January 2024

WuXi AppTec
Company typePublic
SSE: 603259
IndustryContract Research Organizations
Pharmaceutical
Biopharmaceutical
Medical Devices
Founded2000
HeadquartersShanghai, China
Number of locations
18, including in China and USA
Key people
Dr. Ge Li
Number of employees
>14,000 (2017)[1]
Websitewww.wuxiapptec.com

WuXi AppTec (WuXi is pronounced as Wu-shee) is a global pharmaceutical, biopharmaceutical, and medical device company.

The company covers the development cycle through five core operations, including small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics.

History

WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Dr. Ge Li.[2] [3]

WuXi PharmaTech established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006.[4] The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. Following this acquisition, the company was renamed WuXi AppTec.[5] In the same year the company was renamed WuXi AppTec.[6] WuXi AppTec opened a toxicology facility in Suzhou in 2009.[7]

WuXi AppTec's subsidiary, WuXi STA, opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi AppTec acquired MedKey, a China-based clinical research company,[8] and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery.[9] In 2012, WuXi AppTec opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi AppTec also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market.[10] In 2013, WuXi AppTec formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China.[11]

In 2014, WuXi AppTec opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi AppTec acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.[12]

In 2015, WuXi AppTec completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion.[13] In 2016, WuXi STA opened a new campus in Changzhou[14] and operations in San Diego. In the same year, WuXi AppTec acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany.[15] In 2017, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).[16]

Company segments and subsidiaries

WuXi AppTec provides services to its customers primarily in the pharmaceutical, biotech, and other life science industries, as well as research institutes, disease-focused and non-profit foundations. There are 5 areas of focus for services:[citation needed]

  1. Small Molecule Therapeutics R&D, Manufacturing and Testing
  2. Biologicals Therapeutics R&D and Manufacturing
  3. Gene- and Cell-based Therapies Manufacturing
  4. Medical Device Testing
  5. Genomics and Molecular Diagnostics.

WuXi NextCODE

In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013.[17][18] The subsidiary had offices in Boston and Woburn, Massachusetts (US); Reykjavik (Iceland) and Shanghai (China).[18]

References

  1. ^ "Company Profile". WuXi AppTec. Archived from the original on 5 July 2017. Retrieved 12 July 2017.
  2. ^ "Company Profile/ leadership". WuXi AppTec. Retrieved 29 March 2021.
  3. ^ "Company Profile/ History". WuXi AppTec. Retrieved 29 March 2021.
  4. ^ "WuXi PharmaTechListed Among Asia's Fastest Growing Companies, Third Year Running" (Press release). WuXi PharmaTech. 14 December 2006. Retrieved 24 June 2020 – via PRNewswire.
  5. ^ Nagaraj, Amulya; Shen, Samuel (4 January 2008). "WuXi to acquire U.S.-based biopharmaceutical company". reuters.com.
  6. ^ "Our History". WuXi AppTec. Retrieved 26 December 2023.
  7. ^ "Our History". WuXi AppTec. 29 March 2019. Retrieved 24 June 2020.
  8. ^ [ https://www.genengnews.com/topics/drug-discovery/wuxi-acquires-chinese-clinical-cros-medkey-and-jiecheng/ WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng] 24 October 2011 www.genengnews.com, accessed 28 March 2021
  9. ^ [ https://www.fiercebiotech.com/biotech/wuxi-pharmatech-acquires-abgent-a-leading-producer-of-biological-research-reagents WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents] 14 October 2011 www.fiercebiotech.com, accessed 28 March 2021
  10. ^ [ https://www.biospectrumasia.com/news/28/1330/medimmune-wuxi-form-joint-venture.html MedImmune, WuXi form joint venture] 10 September 2012 www.biospectrumasia.com, accessed 28 March 2021
  11. ^ [ http://www.pmlive.com/pharma_news/wuxi_and_pra_form_chinese_joint_venture_458040 WuXi and PRA form Chinese joint venture] 8 January 2013 www.pmlive.com, accessed 28 March 2021
  12. ^ [ https://www.thepharmaletter.com/article/wuxi-pharmatech-acquires-xenobiotic-labs WuXi PharmaTech acquires XenoBiotic Labs] 1 October 2014 www.thepharmaletter.com, accessed 28 March 2021
  13. ^ [ https://www.conyers.com/publications/view/conyers-advises-new-wuxi-life-science-ltd-in-connection-with-us-3-3-billion-buyout/ Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout] www.conyers.com, accessed 29 March 2021
  14. ^ [ https://www.biospace.com/article/releases/wuxi-apptec-s-sta-subsidiary-opens-new-campus-in-changzhou-/ WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou] 4 March 2016 www.biospace.com, accessed 29 March 2021
  15. ^ [ https://biopharma-asia.com/sections/wuxi-apptec-acquire-crelux-gmbh/ WuXi Apptec acquire Crelux GmbH] 19 April 2016 biopharma-asia.com, accessed 29 March 2021
  16. ^ [ https://www.centerwatch.com/articles/14195 WuXi AppTec acquires HD Biosciences] 20 January 2017 www.centerwatch.com, accessed 29 March 2021
  17. ^ Fidler, Ben (23 October 2013). "DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris". Xconomy. Boston. Retrieved 24 June 2020.
  18. ^ a b "WuXi NextCode". Fast Company. 22 April 2020. Retrieved 24 June 2020.
  19. ^ WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results
  20. ^ WuXi PharmaTech Announces First-Quarter 2013
Retrieved from "https://en.wikipedia.org/w/index.php?title=WuXi_AppTec&oldid=1193417035"